Pharmacology of cannabinoid receptor agonists and a cyclooxygenase-2 inhibitor in rat bone tumor pain

Pharmacology

Volumn 92, Issue 3-4, 2013, Pages 150-157

  Cui, Jin Hua ^a   Ju, Jin ^a   Yoon, Myung Ha ^a,b  

^a Chonnam National University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Bone tumor pain; Cannabinoid 1 and cannabinoid 2 receptor agonists; Cyclooxygenase 2 inhibitor; Spinal cord; Sprague Dawley rat

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACEA; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; MESSENGER RNA; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE PAIN; BONE TUMOR; BONE TUMOR PAIN; CARCINOMA CELL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD; WESTERN BLOTTING; BEHAVIOR CHANGE; CANCER PAIN; OSTEOLYSIS; RNA ISOLATION;

ANIMALS; ARACHIDONIC ACIDS; BONE NEOPLASMS; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HYPERALGESIA; PAIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; SPINAL CORD; THIOPHENES; TIBIA;

EID: 84888068128     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000354296     Document Type: Article

References (39)

1. Mercadante S: Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18.
2. Sabino MA, Mantyh PW: Pathophysiology of bone cancer pain. J Support Oncol 2005; 3: 15-24.
3. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, et al: Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000; 98: 585-598.
4. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, et al: Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999; 19: 10886-10897.
5. Mechoulam R, Shani A, Edery H, Grunfeld Y: Chemical basis of hashish activity. Science 1970; 169: 611-612.
6. Tuboly G, Mecs L, Benedek G, Horvath G: Antinociceptive interactions between anandamide and endomorphin-1 at the spinal level. Clin Exp Pharmacol Physiol 2009; 36: 400-405.
7. Furuse S, Kawamata T, Yamamoto J, Niiyama Y, Omote K, Watanabe M, et al: Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain. Anesthesiology 2009; 111: 173-186.
8. Cui JH, Kim WM, Lee HG, Kim YO, Kim CM, Yoon MH: Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. Neurosci Lett 2011; 493: 67-71.
9. Camu F, Shi L, Vanlersberghe C: The role of COX-2 inhibitors in pain modulation. Drugs 2003; 63: 1-7.
10. Choi CH, Kim WM, Lee HG, Jeong CW, Kim CM, Lee SH, et al: Roles of opioid receptor subtype in the spinal antinociception of selective cyclooxygenase 2 inhibitor. Korean J Pain 2010; 23: 236-241.
11. Hefferan MP, Carter P, Haley M, Loomis CW: Spinal nerve injury activates prostaglandin synthesis in the spinal cord that contributes to early maintenance of tactile allodynia. Pain 2003; 101: 139-147.
12. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, et al: Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002; 62: 7343-7349.
13. Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 17: 1031-1036.
14. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55-63.
15. Storr M, Gaffal E, Saur D, Schusdziarra V, Allescher HD: Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol 2002; 80: 67-76.
16. Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K: Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 2002; 303: 1248-1254.
17. Tallarida RJ: Drug Synergism and Dose-Effect Data Analysis, ed 1. New York, Chapman & Hall/CRC, 2000.
18. Rubens RD: Bone metastases - the clinical problem. Eur J Cancer 1998; 34: 210-213.
19. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176.
20. Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, et al: A rat model of bone cancer pain. Pain 2002; 96: 129-140.
21. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P: Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 2005; 132: 1093-1102.
22. Yoon MH, Choi JI: Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology 2003; 99: 701-707.
23. Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA: Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 2008; 108: 722-734.
24. Curto-Reyes V, Llames S, Hidalgo A, Menendez L, Baamonde A: Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 2010; 160: 561-573.
25. Gu X, Mei F, Liu Y, Zhang R, Zhang J, Ma Z: Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D -aspartic acid. Anesth Analg 2011; 113: 405-411.
26. Potenzieri C, Harding-Rose C, Simone DA: The cannabinoid receptor agonist, WIN 55,212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 2008; 1215: 69-75.
27. Hamamoto DT, Giridharagopalan S, Simone DA: Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol 2007; 558: 73-87.
28. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, et al: A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 2003; 103: 175-186.
29. Rahn EJ, Makriyannis A, Hohmann AG: Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007; 152: 765-777.
30. Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, et al: Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993; 307: 361-368.
31. Flower RJ: The development of COX2 inhibitors. Nat Rev Drug Discov 2003; 2: 179-191.
32. Ahmadi S, Lippross S, Neuhuber WL, Zeilhofer HU: PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 2002; 5: 34-40.
33. Baba H, Kohno T, Moore KA, Woolf CJ: Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci 2001; 21: 1750-1756.
34. Beiche F, Brune K, Geisslinger G, Goppelt-Struebe M: Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res 1998; 47: 482-487.
35. Hald A, Ding M, Egerod K, Hansen RR, Konradsen D, Jorgensen SG, et al: Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Pharmacol Biochem Behav 2008; 91: 38-46.
36. Vit JP, Ohara PT, Tien DA, Fike JR, Eikmeier L, Beitz A, et al: The analgesic effect of low dose focal irradiation in a mouse model of bone cancer is associated with spinal changes in neuro-mediators of nociception. Pain 2006; 120: 188-201.
37. Hillard CJ, Manna S, Greenberg MJ, Dicamelli R, Ross RA, Stevenson LA, et al: Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 1999; 289: 1427-1433.
38. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, et al: In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 2006; 149: 145-154.
39. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, et al: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 1995; 305: 479-484.